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Ø OsMed Health-DB Database has been developed to support different health care professionals (e.g. Regions, Local Health Units (LHUs), General Practitioners, specialists) in the monitoring of the compliance of prescribing with therapeutic care standards and in assessing the effects of measures implemented to improve the adherence to these standards. 
Ø

OSMED HEALTH-DB DATABASE CHARACTERISTICS
DATA INCLUSION THERAPEUTIC AREAS
For each LHU the following currents administrative flows have been acquired:
• demographic data (including deaths);
• standard pharmaceutical distribution;
• direct pharmaceutical distribution;
• per conto pharmaceutical distribution;
• hospital discharge records.
For some LHUs, the flow of laboratories was experimentally acquired and used to design/define and calculate diabetes mellitus medicines indicators. Information from these flows was combined through a data linkage procedure on the patient identification (ID) code. Each indicator has been selected based on the assumption that its increase is closely associated with an improvement in the ︎ ︎ ︎ ︎ ︎ ︎ ︎ ︎ ︎ ︎ ︎ ︎ ︎ ︎ ︎ ︎ ︎ ︎ ︎ ︎ ︎ ︎ ︎ ︎ and in a more efficient allocation of resources. For example, prescription compliance with treatment recommendations increases the chances of achieving a favorable therapeutic outcome and, at the same time, reduces the probability of resorting to other services (such as diagnostic tests, treatment for side effects, hospital admissions) and therefore ultimately decreases the overall cost for patient care. In other words, the selection of indicators was made both on a clinical and on an economic basis.
THE HEALTH-DB PROJECT INDICATORS HAVE TWO MAIN OBJECTIVES:
2. FINANCIAL SUSTAINABILITY These indicators have been selected as they are "iso︎ ︎ ︎ ︎ ︎ ︎ -resources"︎ ︎ within the programmed pharmaceutical expenditure budget. All indicators are cost-effective in the medium term, as the improvement of the outcomes results in a decrease of exacerbations, hospitalizations and thus of overall costs for patients care.
THERAPEUTIC APPROPRIATENESS (individual and collective)
Ø Regional Decrees to establish measures (homogeneous) to assess therapeutic appropriateness and the rational use of resources; Ø Estimation of the budget (and needs) of pharmaceutical expenditure (under spending -and overspending areas) under the right of therapeutic appropriateness and rational use of resources; Ø Evidence the level of transfer of the therapeutic recommendations in clinical practice and, accordingly, of the intervention priorities towards areas of greater inappropriateness; Ø Involvement of Physicians in a virtuous process of improving the prescription appropriateness rather than reducing the prescription variability. 
